Media coverage about NantHealth (NYSE:NH) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. NantHealth earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.0273852866906 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Several analysts have issued reports on NH shares. Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 target price (down previously from $8.00) on shares of NantHealth in a research note on Monday, August 21st. Jefferies Group LLC cut their target price on NantHealth from $5.50 to $5.00 and set a “buy” rating for the company in a research note on Wednesday, August 23rd. BidaskClub raised NantHealth from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th. Finally, Zacks Investment Research raised NantHealth from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. NantHealth has a consensus rating of “Buy” and a consensus price target of $8.30.
Shares of NantHealth (NYSE:NH) traded down 4.73% during mid-day trading on Wednesday, reaching $3.83. The company’s stock had a trading volume of 134,304 shares. The company’s 50-day moving average price is $4.39 and its 200-day moving average price is $4.39. NantHealth has a 12-month low of $2.60 and a 12-month high of $13.88. The stock’s market capitalization is $467.05 million.
NantHealth (NYSE:NH) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.32). NantHealth had a negative net margin of 267.11% and a negative return on equity of 83.97%. The business had revenue of $26.23 million for the quarter, compared to analysts’ expectations of $31.28 million. During the same quarter in the previous year, the firm earned ($0.15) EPS. NantHealth’s revenue was down 16.7% compared to the same quarter last year. On average, equities research analysts forecast that NantHealth will post ($0.70) earnings per share for the current fiscal year.
In other NantHealth news, COO Ronald Allen Louks sold 26,820 shares of the company’s stock in a transaction on Friday, October 6th. The stock was sold at an average price of $4.28, for a total value of $114,789.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
WARNING: “NantHealth (NH) Receives News Sentiment Score of 0.22” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.com-unik.info/2017/10/18/nanthealth-nh-receives-news-sentiment-score-of-0-22.html.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
What are top analysts saying about NantHealth Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NantHealth Inc and related companies.